GlassScriptPhysician profile
Ashley J Barrat
NPI 1619257797
$12,102.13
in general payments reported to CMS, 2019-2025
50 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,703 · 2022: $2,737 · 2023: $3,622 · 2024: $2,346 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,662.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,409.84 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,564.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $843.64 | 2021-2025 | Breztri, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.59 | 2021-2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $549.86 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $536.51 | 2021-2025 | |
| Amgen INC. | $452.34 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $408.05 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $407.63 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $399.97 | 2021-2024 | |
| Lundbeck LLC | $387.63 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $289.68 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $274.66 | 2021-2025 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.66 | 2021-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $245.12 | 2021-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Barrat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.